These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 31115593)

  • 1. Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)-a report on phase III.
    Niedeggen C; Singer S; Groth M; Petermann-Meyer A; Röth A; Schrezenmeier H; Höchsmann B; Brümmendorf TH; Panse J
    Ann Hematol; 2019 Jul; 98(7):1547-1559. PubMed ID: 31115593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II.
    Groth M; Singer S; Niedeggen C; Petermann-Meyer A; Röth A; Schrezenmeier H; Höchsmann B; Brümmendorf TH; Panse J
    Ann Hematol; 2017 Feb; 96(2):171-181. PubMed ID: 27837250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria.
    Weitz I; Meyers G; Lamy T; Cahn JY; Uranga MT; García Vela JA; Sanz MA; Severino B; Kelly RJ; Hillmen P; Hill A
    Intern Med J; 2013 Mar; 43(3):298-307. PubMed ID: 22909078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH).
    Weisshaar K; Ewald H; Halter J; Gerull S; Schönfeld S; Senft Y; Martinez M; Leuppi-Taegtmeyer A; Khanna N; Maier B; Risitano A; Peffault de Latour R; Tichelli A; Passweg J; Drexler B
    Orphanet J Rare Dis; 2020 Sep; 15(1):249. PubMed ID: 32943103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A brief instrument to measure health-related quality-of-life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10).
    Marschner N; Wilke J; Reschke D; Kaiser F; Schmoor C; Grugel R; Boller E
    J Med Econ; 2018 Sep; 21(9):920-929. PubMed ID: 29874105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26.
    Sztankay M; Aaronson NK; Arraras JI; Basso U; Bumbasirevic U; Efficace F; Giesinger JM; Johnson CD; van Leeuwen M; Oberguggenberger AS; Sosnowski R; Young T; Holzner B;
    BMC Cancer; 2018 Nov; 18(1):1104. PubMed ID: 30419889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15.
    Hjermstad MJ; Bergenmar M; Bjordal K; Fisher SE; Hofmeister D; Montel S; Nicolatou-Galitis O; Pinto M; Raber-Durlacher J; Singer S; Tomaszewska IM; Tomaszewski KA; Verdonck-de Leeuw I; Yarom N; Winstanley JB; Herlofson BB;
    Support Care Cancer; 2016 Sep; 24(9):3915-24. PubMed ID: 27113466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.
    Escalante CP; Chisolm S; Song J; Richardson M; Salkeld E; Aoki E; Garcia-Manero G
    Cancer Med; 2019 Feb; 8(2):543-553. PubMed ID: 30632713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No impact of Asian ethnicity on EORTC QLQ-C30 scores: Group differences and differential item functioning in paroxysmal nocturnal hemoglobinuria.
    Schwartz CE; Stark RB; Borowiec K; Myren KJ
    Health Qual Life Outcomes; 2021 Sep; 19(1):228. PubMed ID: 34583705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data.
    Cella D; Johansson P; Ueda Y; Tomazos I; Gustovic P; Wang A; Patel AS; Schrezenmeier H
    J Patient Rep Outcomes; 2023 Jul; 7(1):63. PubMed ID: 37405515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of abnormal clones by the fluorescent aerolysin method in paroxysmal nocturnal haemoglobinuria and other marrow disorders.
    Agarwal R; Chapple P; Brown M; Szer J; Juneja S
    Int J Lab Hematol; 2015 Feb; 37(1):14-21. PubMed ID: 24702736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study.
    Kulagin A; Lisukov I; Ivanova M; Golubovskaya I; Kruchkova I; Bondarenko S; Vavilov V; Stancheva N; Babenko E; Sipol A; Pronkina N; Kozlov V; Afanasyev B
    Br J Haematol; 2014 Feb; 164(4):546-54. PubMed ID: 24261566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group.
    Flechtner H; Rüffer JU; Henry-Amar M; Mellink WA; Sieber M; Fermé C; Eghbali H; Josting A; Diehl V
    Ann Oncol; 1998; 9 Suppl 5():S147-54. PubMed ID: 9926255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of clinical paroxysmal nocturnal haemoglobinuria in children with aplastic anaemia.
    Narita A; Muramatsu H; Okuno Y; Sekiya Y; Suzuki K; Hamada M; Kataoka S; Ichikawa D; Taniguchi R; Murakami N; Kojima D; Nishikawa E; Kawashima N; Nishio N; Hama A; Takahashi Y; Kojima S
    Br J Haematol; 2017 Sep; 178(6):954-958. PubMed ID: 28643364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.
    Almeida AM; Bedrosian C; Cole A; Muus P; Schrezenmeier H; Szer J; Rosse WF
    Intern Med J; 2017 Sep; 47(9):1026-1034. PubMed ID: 28608499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26.
    Holzner B; Efficace F; Basso U; Johnson CD; Aaronson NK; Arraras JI; Smith AB; Chow E; Oberguggenberger AS; Bottomley A; Steiner H; Incrocci L; Giesinger JM
    Qual Life Res; 2013 Mar; 22(2):369-78. PubMed ID: 22407356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study.
    Koller M; Shamieh O; Hjermstad MJ; Hornslien K; Young T; Chalk T; Ioannidis G; Harle A; Johnson CD; Tomaszewski KA; Serpentini S; Pinto M; van der Weijst L; Janssens A; Morag O; Chie WC; Arraras JI; Pompili C; Jungraithmayr W; Hechtner M; Katsochi D; Müller K; Gräfenstein L; Schulz C; Bottomley A; ; ;
    Lancet Oncol; 2020 May; 21(5):723-732. PubMed ID: 32213338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychometric properties of the EORTC QLQ-C30 in Uganda.
    Naamala A; Eriksson LE; Orem J; Nalwadda GK; Kabir ZN; Wettergren L
    Health Qual Life Outcomes; 2021 Apr; 19(1):131. PubMed ID: 33892718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
    Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.
    Ueda Y; Obara N; Yonemura Y; Noji H; Masuko M; Seki Y; Wada K; Matsuda T; Akiyama H; Ikezoe T; Chiba S; Kanda Y; Kawaguchi T; Shichishima T; Nakakuma H; Okamoto S; Nishimura JI; Kanakura Y; Ninomiya H
    Int J Hematol; 2018 Jun; 107(6):656-665. PubMed ID: 29383624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.